Too often, patients get expensive, reactive, fragmented care that doesnt actually make them healthier
Wellner, V
He replied that he would have rather won a Heisman by playing halfback for the California Golden Bears
Novo Nordisk will almost certainly launch with: A savings card for patients with commercial insurance (reducing costs to $25$50/month in many cases) A patient assistance program for income-qualifying uninsured patients Possible direct-to-consumer pricing through NovoCare Pharmacy, similar to Wegovys $349/month self-pay model
On October 22, 2024, Novo Nordisk submitted a nomination to the FDA, arguing that semaglutide products belong on the Demonstrable Difficulties for Compounding (DDC) list due to the complexities associated with their formulations, delivery mechanisms, dosage forms, achievement of bioavailability, compounding processes, and physicochemical and analytical testing. The FDA has yet to make a final decision on whether to ban compounded versions of semaglutide
Lastly, the observational design, lack of standardized outcome measures, small sample size and heterogeneity of responses to semaglutide treatment, likely due to the complex nature of obesity in PWS, reduces the generalizability of the findings to a wider population
